Compare iShares Global Tech ETF (IXN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Sanofi SA — how do they compare? iShares Global Tech ETF trades at $142.56, while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while iShares Global Tech ETF pays none, and iShares Global Tech ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| IXN | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $52.34 |
52-Week Low | $94.42 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $142.54, up 2.24% with strong technical momentum as moving averages signal bullish sentiment. The ETF shows robust technical positioning near resistance levels while maintaining neutral oscillator readings. Recent dividend activity and global tech exposure highlight its investment profile.
Outlook remains cautiously optimistic given high valuations and concentration risks in tech holdings. Key opportunities include AI-driven growth exposure, while risks involve stretched valuations and sector volatility. Analyst consensus suggests holding for strategic tech allocation.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
